These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
604 related articles for article (PubMed ID: 18949375)
1. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375 [TBL] [Abstract][Full Text] [Related]
2. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cunningham MP; Thomas H; Fan Z; Modjtahedi H Cancer Res; 2006 Aug; 66(15):7708-15. PubMed ID: 16885373 [TBL] [Abstract][Full Text] [Related]
4. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Moser C; Schachtschneider P; Lang SA; Gaumann A; Mori A; Zimmermann J; Schlitt HJ; Geissler EK; Stoeltzing O Eur J Cancer; 2008 Jul; 44(11):1577-86. PubMed ID: 18445520 [TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634 [TBL] [Abstract][Full Text] [Related]
7. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284 [TBL] [Abstract][Full Text] [Related]
8. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. Baumann P; Hagemeier H; Mandl-Weber S; Franke D; Schmidmaier R Anticancer Drugs; 2009 Apr; 20(4):259-66. PubMed ID: 19240643 [TBL] [Abstract][Full Text] [Related]
9. NO donor and MEK inhibitor synergistically inhibit proliferation and invasion of cancer cells. Furuhashi S; Sugita H; Takamori H; Horino K; Nakahara O; Okabe H; Miyake K; Tanaka H; Beppu T; Baba H Int J Oncol; 2012 Mar; 40(3):807-15. PubMed ID: 22025280 [TBL] [Abstract][Full Text] [Related]
10. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression. Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478 [TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Slomiany MG; Black LA; Kibbey MM; Tingler MA; Day TA; Rosenzweig SA Cancer Lett; 2007 Apr; 248(2):269-79. PubMed ID: 16996205 [TBL] [Abstract][Full Text] [Related]
16. Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity. Bao XH; Takaoka M; Hao HF; Wang ZG; Fukazawa T; Yamatsuji T; Sakurama K; Sun DS; Nagasaka T; Fujiwara T; Naomoto Y Anticancer Res; 2012 Jul; 32(7):2827-34. PubMed ID: 22753744 [TBL] [Abstract][Full Text] [Related]
17. RAV12 accelerates the desensitization of Akt/PKB pathway of insulin-like growth factor I receptor signaling in COLO205. Li JC; Li R Cancer Res; 2007 Sep; 67(18):8856-64. PubMed ID: 17875727 [TBL] [Abstract][Full Text] [Related]
18. Effect of epidermal growth factor receptor inhibitor alone and in combination with cisplatin on growth of vulvar cancer cells. Kim SH; Song YC; Kim SH; Jo H; Song YS Ann N Y Acad Sci; 2009 Aug; 1171():642-8. PubMed ID: 19723115 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours. Browne BC; Eustace AJ; Kennedy S; O'Brien NA; Pedersen K; McDermott MS; Larkin A; Ballot J; Mahgoub T; Sclafani F; Madden S; Kennedy J; Duffy MJ; Crown J; O'Donovan N Breast Cancer Res Treat; 2012 Dec; 136(3):717-27. PubMed ID: 23117852 [TBL] [Abstract][Full Text] [Related]
20. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Cunningham MP; Essapen S; Thomas H; Green M; Lovell DP; Topham C; Marks C; Modjtahedi H Int J Oncol; 2006 Feb; 28(2):329-35. PubMed ID: 16391786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]